Fatal Familial Insomnia: An In-Depth Look at Symptoms, Diagnosis, and Management

Fatal Familial Insomnia (familial insomnia or FFI) is an exceptionally rare and universally fatal neurodegenerative prion disease. This inherited condition stems from an autosomal dominant mutation within the prion protein (PRNP) gene. The disease is characterized by a devastating progression of insomnia, followed by a cascade of autonomic malfunctions, including rapid heart rate (tachycardia), excessive sweating (hyperhidrosis), and elevated blood pressure (hypertension). Cognitive impairments manifest as deficits in short-term memory and attention, accompanied by balance disturbances and endocrine irregularities. Currently, there is no cure for familial insomnia, and the average course of the illness is a harrowing 18 months, culminating in death. Accurate diagnosis relies heavily on a thorough patient history and neurological examination, as familial insomnia is primarily diagnosed clinically. Treatment strategies are currently limited to symptomatic relief and palliative care, aimed at managing the distressing symptoms as effectively as possible. This resource is designed for healthcare professionals to improve their knowledge in selecting appropriate diagnostic evaluations, managing familial insomnia, and fostering effective collaborative care to optimize patient outcomes.

Learning Objectives:

• Distinguish the defining symptoms of familial insomnia from other sleep disorders.
• Implement evidence-based management strategies for familial insomnia, focusing on both symptom control and comprehensive supportive care.
• Utilize appropriate palliative care measures to alleviate suffering and improve the patient’s quality of life.
• Develop interprofessional team approaches to enhance care coordination in familial insomnia management and improve patient outcomes.

Delving into Familial Insomnia

Fatal familial insomnia (familial insomnia or FFI) stands as a remarkably rare, inherited, and invariably fatal neurodegenerative prion disease. Its autosomal dominant inheritance pattern involves a mutation in the prion protein (PRNP) gene, leading to the degeneration of the thalamic nucleus.[1, 2] Hallmarks of this condition include relentlessly progressive insomnia, coupled with subsequent autonomic dysregulation (e.g., tachycardia, hyperhidrosis, hypertension), cognitive decline (e.g., short-term memory and attention deficits), motor system impairments (e.g., balance problems), and endocrine dysfunction. Presently, familial insomnia remains incurable, with a typical disease progression of approximately 18 months, ultimately leading to death.

Historical accounts trace the earliest descriptions of familial insomnia back to 1765, detailing an Italian man exhibiting symptoms suggestive of the condition. However, it was formally identified and clinically delineated in 1986 by Lugaresi E and colleagues, with subsequent research further elucidating its pathophysiology, etiology, and clinical trajectory.[3, 4] Given the absence of a definitive cure, diagnosis hinges upon meticulous history taking and neurological assessments, underscoring its primarily clinical nature. Current therapeutic interventions are confined to symptomatic management and palliative care, aiming to alleviate suffering and improve comfort.

Unraveling the Etiology of Familial Insomnia

Familial insomnia is categorized within a group of genetic human prion diseases, which also includes familial Creutzfeldt-Jakob disease, prion protein amyloidosis, Gerstmann-Straussler-Scheinker syndrome, and Huntington disease-like 1.[2] The root cause of familial insomnia is attributed to an autosomal dominant mutation at codon 178 of the PRNP gene. This gene resides on the short (p) arm of chromosome 20 at position p13 (20p13), and is responsible for producing the normal prion protein, PrPC. Inherited mutations in the PRPN gene account for roughly 10% to 15% of all prion disease diagnoses. Specifically, familial insomnia arises from a D178N mutation, linked to the M129 genotype within the pPrPC gene. While the precise timing of disease onset is not fully understood, evidence suggests that it is linked to the accumulation of a critical mass of prion protein that converts into the aberrant prion protein form.[4, 5, 6]

Epidemiology of Familial Insomnia

Globally, documented cases of familial insomnia number in the hundreds, with a higher prevalence in Europe and Asia. Notably, there has been an increasing trend in recent years, particularly in China.[7] A comprehensive analysis of 131 FFI patients revealed 57 women and 72 men. The average age of disease onset was 47.5 years, with a range spanning from 17 to 76 years. Among these patients, 106 deaths were reported, and the average disease duration was 13.2 months, ranging from 2 to 48 months.[8] The observed variations in disease characteristics across different regions and genetic backgrounds are areas of ongoing scientific investigation. A small-scale study indicated that a specific genetic variation at codon 129 of PRNP might be associated with the diverse features of familial insomnia. Among Asian populations, symptoms such as movement abnormalities, sleep-related breathing difficulties, and laryngeal stridor are more commonly observed. Additionally, another distinct cluster presented with hypertension, excessive perspiration, and weight loss. Conversely, Asians exhibit lower rates of diplopia (double vision) and myoclonus compared to other ethnic groups.[8] Overall, genetic prion diseases are exceedingly rare, with an annual incidence of 1 to 1.5 new cases of genetic and non-genetic prion diseases per 1 million individuals.[9] Hereditary forms of prion disease comprise approximately 10% of all prion disease cases.[1]

Pathophysiology of Familial Insomnia

The neuropathological changes in familial insomnia include neuronal loss and gliosis, predominantly affecting the thalamus. This brain region plays a crucial role in various sensory and motor functions, as well as sleep regulation.[10] These pathological alterations directly contribute to the clinical manifestations of familial insomnia, notably the severe sleep disturbances and autonomic dysfunction. The spread of these pathological changes to other brain areas explains the diverse clinical features observed in individuals with familial insomnia.

Studies have shown that the parietal, temporal, and frontal lobes are more significantly affected than the occipital lobe. Furthermore, the degree of brain cortex involvement, indicated by spongiosis and astrogliosis, correlates positively with the duration of the disease. However, the deposition pattern of the prion protein tends to favor the brainstem and thalamus in the earlier stages, with the thalamus experiencing the most pronounced degenerative changes. The underlying reasons for this specific pattern of involvement remain poorly understood, but it likely contributes to the wide spectrum of symptoms seen in this disease.[4, 6, 9]

Histopathology of Familial Insomnia

Western blot and immunocytochemistry analyses of human brains have revealed a disconnect between the quantity and location of prion protein deposits, the protease-resistant form, and the severity of histopathological changes. A study examining the cerebellar cortex of a patient revealed a high concentration of prion protein deposits in the molecular layer, displaying a unique patchy and strip-like pattern oriented perpendicular to the surface.[11] In another patient from the same study, a single neuron within the inferior olivary nuclei contained abundant protease-resistant prion protein deposits within its vacuoles, resembling the changes observed in brainstem neurons in bovine spongiform encephalopathy.

Clinical Presentation: History and Physical Examination of Familial Insomnia

The typical age of symptom onset for familial insomnia ranges from 20 to 61 years, with an average age of 50 years. Familial insomnia often presents with varied clinical phenotypes and significant neuronal loss and gliosis, particularly in the thalamus.[12] A detailed medical history and neurological examination are crucial, as familial insomnia is primarily a clinical diagnosis. When assessing a patient suspected of having familial insomnia, the following diagnostic clinical features should be considered:

Diagnostic Clinical Features

In 2022, an international consensus group established diagnostic clinical criteria to aid in differentiating familial insomnia from other conditions with similar symptoms and to facilitate earlier disease identification. The duration of the following core symptoms is typically:

• Organic sleep disturbances: Including intractable insomnia, agrypnia excitata (agitated sleeplessness) with or without laryngeal stridor, sleep apnea, or involuntary movements (e.g., hypnic jerks, restless sleep with frequent position changes).
• Neurologic and mental health impairment: Including rapidly progressive dementia, ataxia, myoclonus, hallucinations, delusions, or personality changes (e.g., depression, anxiety, apathy, and confusion).
• Progressive autonomic and systemic abnormalities: Including hypertension, tachycardia, irregular breathing, hyperthermia, excessive sweating, or unintentional weight loss exceeding 10 kg within the preceding 6 months [20].

In addition to these core clinical features, the following findings support a diagnosis of familial insomnia:

• Family history of organic insomnia symptoms.
• Probable organic insomnia (e.g., loss of circadian rhythm, fragmented sleep, reduced total sleep time, or sleep–wake cycle disruption) with or without involuntary movements observed on video polysomnography [20].

Evaluation and Diagnosis of Familial Insomnia

Familial insomnia is primarily a clinical diagnosis; however, various diagnostic studies are typically conducted to support the diagnosis and exclude other potential conditions.[20]

Diagnostic Studies

• Initial laboratory workup: Should include a complete blood count (CBC), erythrocyte sedimentation rate (ESR), serum chemistry, liver function tests (LFTs), ammonia levels, and blood cultures to rule out suspected bacterial infections.
• Evaluation for reversible causes of cognitive decline: Should include thyroid function tests (TFTs), vitamin B-12 and folate levels, along with testing for neurosyphilis and human immunodeficiency virus (HIV).
• Polysomnography (PSG): Can reveal a reduction in total sleep time and dysfunctional transitions between sleep stages. Specifically, PSG typically shows reduced REM sleep, decreased sleep efficiency, and slow wave sleep.[12]
• Electroencephalogram (EEG): Periodic sharp-wave complexes (PSWC) may suggest prion disease but are observed in only a small proportion of patients with genetic forms of prion disease. Pathogenic variants characterized by pronounced spongiform degeneration and a CJD-like clinical presentation are more likely to exhibit an abnormal EEG. Although non-specific, patients with familial insomnia often show generalized slowing without periodic sharp-wave complexes.[12]
• Cerebrospinal Fluid (CSF) studies: Biomarkers such as 14-3-3 protein are non-specific and may be elevated in various conditions causing neuronal death.

Imaging Studies

• Computed tomography (CT) and magnetic resonance imaging (MRI): Have limited diagnostic utility in familial insomnia but can help exclude other neurological pathologies.
• Diffusion MRI: Reduced thalamic diffusion may be observed due to gliosis. Atrophic changes may become apparent as the disease progresses.
• Fluorodeoxyglucose positron emission tomography (FDG-PET): Examinations can potentially aid in diagnosing familial insomnia. PET imaging may reveal hypometabolism in the thalamic and cingulate regions, typically sparing the occipital lobe.[21]

Molecular Genetic Testing: Genetic testing for targeted analysis of the pathogenic variant of PRNP or full gene sequencing is recommended in suspected patients.

Histopathological Testing: Brain biopsies, while not diagnostic for familial insomnia, may be considered to rule out other neurological diseases.

Diagnostic Approach

Polysomnography and genetic testing are recommended, preceded by comprehensive genetic counseling. Specifically, targeted screening for the D178N mutation of the PRNP gene can facilitate early diagnosis of familial insomnia.[2] While clinical diagnostics provide valuable information, genetic testing and counseling are crucial for confirming the diagnosis and identifying potential risks for family members. Furthermore, targeted screening for specific genetic mutations, such as the D178N mutation of PRNP, plays a key role in establishing an early diagnosis and guiding effective management strategies.[12]

Utilizing the 2022 international consensus group diagnostic criteria, the likelihood of familial insomnia can be categorized. This diagnostic approach incorporates core clinical and supportive features, diagnostic study findings, and exclusionary factors:[20]

• Exclusionary features:
  • Periodic sharp wave complexes on EEG.
  • Hyperintense signal in the caudate nucleus and putamen or ≥2 cortical regions on imaging or MRI sequencing.
  • Clinical presentation better explained by alternative diagnoses.
• Diagnostic studies: Positive molecular genetic testing for PRNP mutation.
• Probability of Familial Insomnia diagnosis based on diagnostic criteria:
  • Possible Familial Insomnia: 2 out of 3 core clinical features without any exclusionary features.
  • Probable Familial Insomnia: 2 out of 3 core clinical features, ≥ 1 supportive feature without any exclusionary features.
  • Definite Familial Insomnia: 2 out of 3 core clinical features and positive diagnostic studies.

Treatment and Management of Familial Insomnia

Treatment for familial insomnia is primarily focused on symptomatic relief and palliative care, as there is currently no cure. Various treatment modalities have been explored in the literature:

• Discontinuation of medications that may worsen confusion, memory impairment, and insomnia is essential.
• Patients with familial insomnia typically exhibit a poor response to sedatives. Tinuper P et al. reported the ineffectiveness of barbiturates or benzodiazepines on EEG activity in FFI patients.[9]
• Swallowing difficulties may necessitate the placement of a feeding tube.
• A case report investigated the use of gamma-hydroxybutyrate (GHB) and found that its administration induced slow-wave sleep (SWS) in a patient with familial insomnia.[22]
• Several experimental treatments using compounds like pentosan polysulfate, quinacrine, and amphotericin B have been studied with inconclusive results.[23]
• A clinical trial is currently underway in Italy to assess the potential for preventing prion disease onset in individuals carrying the PRNP D178N/M129 mutation. This study involves administering doxycycline (100 mg orally daily for 10 years) to 10 carriers and comparing outcomes to a control group of 15 non-carriers from the same family. The trial is ongoing, and results are pending.[24]
• Immunotherapy has shown promising results in vitro and in vivo in animal models and clinical trials. Research is focused on three main types of immunotherapy: antibody vaccines, dendritic cell vaccines, and adoptive transfer of physiological prion protein-specific CD4(+) T-lymphocytes. Antibody vaccines are designed to target unique epitopes present only on the misfolded prion protein form (PrP(Sc)).[25]
• Psychosocial therapy is crucial for both the patient and their family. Hospice care can provide significant support and benefit.

Differential Diagnosis of Familial Insomnia

When evaluating patients with suspected familial insomnia, it is essential to consider other prion diseases due to overlapping symptoms,[6, 26] including:

• Sporadic Creutzfeldt-Jakob disease (sCJD) and familial Creutzfeldt-Jakob disease (fCJD): These conditions share clinical and pathological similarities, although sCJD tends to be more aggressive with a later onset. Both typically present with memory problems and confusion, followed by myoclonus and ataxia. Spongiform degeneration and astrogliosis are generally more pronounced and widespread compared to familial insomnia.[27]
• Sporadic fatal insomnia (sFI): Mimics familial insomnia in genetic, clinical, and histopathological features but lacks a genetic mutation. Like other neurodegenerative diseases, sFI lacks a precise animal model and effective therapeutic intervention. Developing a precise disease model is crucial for understanding the pathogenic mechanism.[28]
• Gerstmann-Straussler-Scheinker syndrome (GSS): Typically presents with cerebellar dysfunction, with minimal sleep disturbance. Cognitive dysfunction is generally less prominent and more likely to occur in later stages. GSS is inherited in an autosomal dominant pattern with high penetrance, attributed to various point mutations and insertion mutations involving octapeptide repeats.[29]
• Variably protease-sensitive prionopathy: Can present with varying degrees of aphasia and behavioral symptoms and is best diagnosed through histopathological examination.
• Lithium toxicity
• Familial myoclonic dementia
• Diffuse Lewy body disease
• Chronic meningitis
• Dementia as a paraneoplastic syndrome
• Dementia in motor neuron disease
• Nonherpes viral encephalitis
• Hashimoto encephalopathy (or steroid-responsive encephalopathy associated with autoimmune thyroiditis [SREAT])
• Limbic encephalitis (and other paraneoplastic syndromes)[30]

Furthermore, it is crucial to rule out other potentially reversible causes of dementia, including herpes encephalitis, paraneoplastic syndromes like limbic encephalitis, Hashimoto encephalitis, lithium poisoning, chronic meningitis, HIV encephalopathy, and hydrocephalus.[30, 31] Neurodegenerative diseases such as Alzheimer’s disease, Pick disease, corticobasal degeneration, multiple system atrophy, frontotemporal dementia, and familial myoclonic dementia, despite their slower progression, should also be considered during the diagnostic evaluation.[32]

Staging of Familial Insomnia

Familial insomnia is characterized by four progressive stages:

• Stage 1: Characterized by the subacute onset of insomnia, worsening over several months, accompanied by psychiatric symptoms such as phobias, paranoia, and panic attacks. Patients may report lucid dreaming during this stage.
• Stage 2: Over the subsequent five months, psychiatric symptoms intensify, insomnia worsens, and hallucinations may occur. Autonomic dysfunction, manifesting as sympathetic hyperactivity, becomes evident.
• Stage 3: This brief stage, lasting approximately three months, is dominated by complete insomnia and complete disruption of the sleep-wake cycle.
• Stage 4: The final stage can extend for six months or longer, marked by rapid cognitive decline and dementia. Patients experience an inability to move or speak voluntarily, progressing to coma and ultimately death.[33]

Prognosis of Familial Insomnia

The disease course of familial insomnia typically ranges from 7 to 36 months, with an average duration of 18 months leading to death. Patients with homozygous (Met-Met) mutation tend to have a shorter mean survival time compared to heterozygous (Met-Val) patients.[34, 35]

Complications of Familial Insomnia

Familial insomnia is invariably fatal. It leads to various autonomic, cognitive, motor, and endocrine complications. (Refer to the “History and Physical” section for detailed information on complications).

Deterrence and Patient Education for Familial Insomnia

Patients and families should receive comprehensive education about the fatal nature of familial insomnia. They should be informed about the currently limited treatment options and the ongoing research efforts. Genetic counseling should be offered to family members to assess and understand their individual risks.

Enhancing Healthcare Team Outcomes for Familial Insomnia

Familial insomnia is a rare, hereditary prion disease characterized by intractable insomnia that leads to severe neurodegeneration. Clinicians must be adept at recognizing its distinctive symptoms, including sleep disturbances and autonomic dysfunction. Early identification through genetic testing is critical. Management strategies are centered around symptomatic relief, palliative care, and a collaborative interprofessional approach. The prognosis remains poor, with death typically occurring within a year of diagnosis.

Optimal management of familial insomnia necessitates an interprofessional team, including sleep specialists, neurologists, psychiatrists and psychologists, social workers, palliative care nurses, and hospice care providers. Hospice involvement should be initiated early in the care trajectory. Psychosocial counseling for family members is also essential. Effective communication within the team and with the patient and family is paramount to navigating the complex challenges of familial insomnia, emphasizing compassionate end-of-life care and addressing psychological and social needs alongside medical considerations.

Review Questions (Not included in rewritten article as per instructions)

References

1.Nafe R, Arendt CT, Hattingen E. Human prion diseases and the prion protein – what is the current state of knowledge? Transl Neurosci. 2023 Jan 01;14(1):20220315. [PMC free article: PMC10579786] [PubMed: 37854584]

2.Bagyinszky E, Giau VV, Youn YC, An SSA, Kim S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr Dis Treat. 2018;14:2067-2085. [PMC free article: PMC6097508] [PubMed: 30147320]

3.Medori R, Montagna P, Tritschler HJ, LeBlanc A, Cortelli P, Tinuper P, Lugaresi E, Gambetti P. Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology. 1992 Mar;42(3 Pt 1):669-70. [PubMed: 1347910]

4.Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? MedGenMed. 2006 Sep 14;8(3):65. [PMC free article: PMC1781306] [PubMed: 17406188]

5.Montagna P, Cortelli P, Avoni P, Tinuper P, Plazzi G, Gallassi R, Portaluppi F, Julien J, Vital C, Delisle MB, Gambetti P, Lugaresi E. Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol. 1998 Jul;8(3):515-20. [PMC free article: PMC8098256] [PubMed: 9669701]

6.Zerr I, Schmitz M. Genetic Prion Disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle; Seattle (WA): Mar 27, 2003. [PubMed: 20301407]

7.Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty. 2016 Jun 02;5(1):47. [PMC free article: PMC4890484] [PubMed: 27251305]

8.Zhang J, Chu M, Tian Z, Xie K, Cui Y, Liu L, Meng J, Yan H, Ji YM, Jiang Z, Xia TX, Wang D, Wang X, Zhao Y, Ye H, Li J, Wang L, Wu L. Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):291-297. [PMC free article: PMC8862016] [PubMed: 34667102]

9.Tinuper P, Montagna P, Medori R, Cortelli P, Zucconi M, Baruzzi A, Lugaresi E. The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration. Electroencephalogr Clin Neurophysiol. 1989 Aug;73(2):117-23. [PubMed: 2473878]

10.Montagna P. Fatal familial insomnia and the role of the thalamus in sleep regulation. Handb Clin Neurol. 2011;99:981-96. [PubMed: 21056239]

11.Almer G, Hainfellner JA, Brücke T, Jellinger K, Kleinert R, Bayer G, Windl O, Kretzschmar HA, Hill A, Sidle K, Collinge J, Budka H. Fatal familial insomnia: a new Austrian family. Brain. 1999 Jan;122 ( Pt 1):5-16. [PubMed: 10050890]

12.Krasnianski A, Bartl M, Sanchez Juan PJ, Heinemann U, Meissner B, Varges D, Schulze-Sturm U, Kretzschmar HA, Schulz-Schaeffer WJ, Zerr I. Fatal familial insomnia: Clinical features and early identification. Ann Neurol. 2008 May;63(5):658-61. [PubMed: 18360821]

13.Plazzi G, Schutz Y, Cortelli P, Provini F, Avoni P, Heikkila E, Tinuper P, Solieri L, Lugaresi E, Montagna P. Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study. Sleep. 1997 Sep;20(9):739-42. [PubMed: 9406326]

14.Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P, Lugaresi A, Tinuper P, Zucconi M, Gambetti P. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986 Oct 16;315(16):997-1003. [PubMed: 3762620]

15.Baldelli L, Provini F. Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications. Auton Neurosci. 2019 May;218:68-86. [PubMed: 30890351]

16.Gallassi R, Morreale A, Montagna P, Gambetti P, Lugaresi E. “Fatal familial insomnia”: neuropsychological study of a disease with thalamic degeneration. Cortex. 1992 Jun;28(2):175-87. [PubMed: 1499304]

17.Cortelli P, Fabbri M, Calandra-Buonaura G, Capellari S, Tinuper P, Parchi P, Lugaresi E. Gait disorders in fatal familial insomnia. Mov Disord. 2014 Mar;29(3):420-4. [PubMed: 24375448]

18.Gallassi R, Morreale A, Montagna P, Cortelli P, Avoni P, Castellani R, Gambetti P, Lugaresi E. Fatal familial insomnia: behavioral and cognitive features. Neurology. 1996 Apr;46(4):935-9. [PubMed: 8780067]

19.Montagna P, Cortelli P, Gambetti P, Lugaresi E. Fatal familial insomnia: sleep, neuroendocrine and vegetative alterations. Adv Neuroimmunol. 1995;5(1):13-21. [PubMed: 7795890]

20.Chu M, Xie K, Zhang J, Chen Z, Ghorayeb I, Rupprecht S, Reder AT, Garay A, Honda H, Nagayama M, Shi Q, Zhan S, Nan H, Zhang J, Guan H, Cui L, Guo Y, Rosa-Neto P, Gauthier S, Wang J, Dong X, Wu L. Proposal of new diagnostic criteria for fatal familial insomnia. J Neurol. 2022 Sep;269(9):4909-4919. [PMC free article: PMC9363306] [PubMed: 35501502]

21.Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, Avoni P, Ferrillo F, Anchisi D, Moresco RM, Fazio F, Parchi P, Baruzzi A, Lugaresi E, Gambetti P. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006 Mar;129(Pt 3):668-75. [PubMed: 16399807]

22.Reder AT, Mednick AS, Brown P, Spire JP, Van Cauter E, Wollmann RL, Cervenàkovà L, Goldfarb LG, Garay A, Ovsiew F. Clinical and genetic studies of fatal familial insomnia. Neurology. 1995 Jun;45(6):1068-75. [PubMed: 7783865]

23.Zerr I. Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets. 2009 Feb;9(1):92-9. [PubMed: 19200019]

24.Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, Erbetta A, Villani F, Redaelli V, Tagliavini F, Artuso V, Roiter I. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion. 2015;9(2):75-9. [PMC free article: PMC4601344] [PubMed: 25996399]

25.Burchell JT, Panegyres PK. Prion diseases: immunotargets and therapy. Immunotargets Ther. 2016;5:57-68. [PMC free article: PMC4970640] [PubMed: 27529062]

26.Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992 Feb 13;326(7):444-9. [PMC free article: PMC6151859] [PubMed: 1346338]

27.Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009 Oct;132(Pt 10):2659-68. [PMC free article: PMC2759336] [PubMed: 19773352]

28.Cracco L, Appleby BS, Gambetti P. Fatal familial insomnia and sporadic fatal insomnia. Handb Clin Neurol. 2018;153:271-299. [PubMed: 29887141]

29.Hainfellner JA, Brantner-Inthaler S, Cervenáková L, Brown P, Kitamoto T, Tateishi J, Diringer H, Liberski PP, Regele H, Feucht M. The original Gerstmann-Sträussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol. 1995 Jul;5(3):201-11. [PubMed: 8520719]

30.Yang TW, Park B, Kim KT, Jun JS, Kim YS, Lee ST, Jung KH, Chu K, Lee SK, Jung KY. Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review. Medicine (Baltimore). 2018 May;97(18):e0646. [PMC free article: PMC6392909] [PubMed: 29718878]

31.Gaudino S, Gangemi E, Colantonio R, Botto A, Ruberto E, Calandrelli R, Martucci M, Vita MG, Masullo C, Cerase A, Colosimo C. Neuroradiology of human prion diseases, diagnosis and differential diagnosis. Radiol Med. 2017 May;122(5):369-385. [PubMed: 28110369]

32.Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015 Nov;39(5):E2. [PubMed: 26646926]

33.Lindsley CW. Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI). ACS Chem Neurosci. 2017 Dec 20;8(12):2570-2572. [PubMed: 29258312]

34.Parchi P, Petersen RB, Chen SG, Autilio-Gambetti L, Capellari S, Monari L, Cortelli P, Montagna P, Lugaresi E, Gambetti P. Molecular pathology of fatal familial insomnia. Brain Pathol. 1998 Jul;8(3):539-48. [PMC free article: PMC8098344] [PubMed: 9669705]

35.Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003 Mar;2(3):167-76. [PubMed: 12849238]